FLGT - Fulgent Genetics, Inc.

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer que.

Jul 09, 2026 12:05 PM • businesswire.com

Fulgent Presents Updated FID-007 Data at ASCO 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled “FID.

Jun 01, 2026 03:00 PM • businesswire.com

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.

May 22, 2026 11:14 AM • globenewswire.com (Hide legal announcements)

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT).

May 21, 2026 01:03 PM • businesswire.com

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The investigation focuses on Fulgent's executive officers and whether investor losses may be recovered under federal securities laws.

May 20, 2026 04:28 AM • globenewswire.com (Hide legal announcements)

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.

May 08, 2026 05:43 AM • globenewswire.com (Hide legal announcements)

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.

May 04, 2026 03:00 AM • businesswire.com

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

May 01, 2026 08:21 AM • seekingalpha.com

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.04 per share a year ago.

May 01, 2026 05:10 AM • zacks.com

Fulgent Reports First Quarter 2026 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Results: Revenue of $71.1 million GAAP loss of $24.8 million, or $(0.80) per share Non-GAAP loss of $11.0 million, or $(0.36) per share Adjusted EBITDA loss of $15.2 million Non-.

May 01, 2026 03:00 AM • businesswire.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of “Hold” by Analysts

Shares of Fulgent Genetics, Inc. (NASDAQ: FLGT - Get Free Report) have been assigned an average recommendation of "Hold" from the five analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company.

Apr 23, 2026 12:24 AM • defenseworld.net

Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago. The abstra.

Apr 22, 2026 12:05 PM • businesswire.com

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.

Apr 17, 2026 11:20 AM • globenewswire.com (Hide legal announcements)

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer question.

Apr 16, 2026 03:30 AM • businesswire.com

FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Fulgent (FLGT) To Contact Him Directly To Discuss Their Options

Apr 01, 2026 12:10 PM • globenewswire.com (Hide legal announcements)

Fulgent Genetics, Inc. (NASDAQ:FLGT) Sees Large Increase in Short Interest

Fulgent Genetics, Inc. (NASDAQ: FLGT - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 2,135,898 shares, a growth of 38.7% from the February 26th total of 1,540,495 shares. Based on an average daily volume of 976,923 shares,

Mar 30, 2026 11:13 PM • defenseworld.net

FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 27, 2026, Fulgent issued a press release reporting its fourth quarter and full year 2025 financial r.

Mar 25, 2026 03:00 PM • businesswire.com (Hide legal announcements)

FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

Mar 23, 2026 02:22 PM • globenewswire.com (Hide legal announcements)

FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.

Mar 19, 2026 04:00 PM • globenewswire.com (Hide legal announcements)

FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 27, 2026, Fulgent issued a press release reporting its fourth quarter and full year 20.

Mar 17, 2026 02:00 PM • businesswire.com (Hide legal announcements)

Fulgent Genetics price target lowered to $15 from $30 at Piper Sandler

$15.00 (was $15.12)

Piper Sandler

May 05, 2026 06:52 AM • TheFly

Fulgent Genetics (FLGT) PT Raised to $36 at Raymond James

$36.00 (was $29.59)

Andrew Cooper · Raymond James

Nov 14, 2025 04:21 AM • StreetInsider

Fulgent Genetics upgraded to Buy from Neutral at UBS

$30.00 (was $20.78)

UBS

Aug 05, 2025 05:29 AM • TheFly

Fulgent Genetics price target lowered to $21 from $23 at Piper Sandler

$21.00 (was $18.36)

Piper Sandler

Aug 04, 2025 06:44 AM • TheFly

Fulgent Genetics price target raised to $25 from $24 at Raymond James

$25.00 (was $19.56)

Andrew Cooper · Raymond James

May 05, 2025 08:09 AM • TheFly

Piper Sandler Downgrades Fulgent Genetics to Neutral, Lowers Price Target to $40

$40.00 (was $37.07)

Piper Sandler

Dec 08, 2022 12:14 AM • Benzinga

Raymond James Initiates Coverage On Fulgent Genetics with Outperform Rating, Announces Price Target of $45

$45.00 (was $35.89)

Raymond James

Nov 18, 2022 02:29 AM • Benzinga

Credit Suisse Maintains Outperform on Fulgent Genetics, Lowers Price Target to $50

$50.00 (was $39.24)

Credit Suisse

Nov 14, 2022 02:30 AM • Benzinga

Fulgent Genetics price target lowered to $70 from $85 at Piper Sandler

$70.00 (was $54.45)

David Westenberg · Piper Sandler

May 15, 2022 05:14 PM • TheFly